Navigation Links
AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
Date:11/14/2012

l trials for ARX-01, that fact that subsequent analyses of the full data set may lead to different, including less favorable, interpretations of the results than the analyses conducted to date or may identify important implications of the study that are not reflected in these statements, or be subject to differing interpretations by the regulatory agencies; the success, cost and timing of all product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials, have an effective design, enroll a sufficient number of patients, or be completed on schedule, if at all; any delays or inability to obtain regulatory approval of its product candidates in the United States and Europe; its ability to obtain adequate clinical supplies of the drug and device components of its product candidates; its ability to attract funding partners or collaborators with development, regulatory and commercialization expertise; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates in the United States and Europe; the market potential for its product candidates; the accuracy of AcelRx Pharmaceuticals' estimates regarding expenses, capital requirements and needs for financing; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the three months ended September 30, 2012. AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
2. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
3. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
4. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
6. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
7. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
8. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
10. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, 2014 ... partner Auxilium Pharmaceuticals, Inc. today announced that the Committee ... European Medicines Agency (EMA) has adopted a positive opinion ... the treatment of adult men with Peyronie,s disease with ... 30 degrees at the start of therapy. ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals Incorporated ... study of lonafarnib in patients with chronic hepatitis ... at the National Institutes of Health (NIH) Clinical ...  The double-blinded, randomized, placebo-controlled, dose ascending study evaluated ... and 200 mg twice daily for 28 days.  ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Nektar Therapeutics (NASDAQ: NKTR ) today ... research scientists at the company,s existing San Francisco ... the UCSF research and medical campus in Mission ... Huntsville, Alabama research site will be relocating to ...
... NEW YORK, March 20, 2012 Reportlinker.com ... is available in its catalogue: ... Global Market Analysis, Size, Share & Forecast ... http://www.reportlinker.com/p0797075/Magnetic-Resonance-Imaging-MRI-Market-Global-Market-Analysis-Size-Share--Forecast-2012---2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging Description ...
Cached Medicine Technology:Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 2Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 3Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 4Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 5Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 2Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 3Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 4
(Date:12/25/2014)... December 25, 2014 When head lice hits ... in a frenzy to get rid of it while keeping ... in Coral Gables now have the solution right in their ... clinic location, Lice Troopers provides full spectrum head lice screening ... Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... can receive effective, less expensive care from a clinic that ... team of dedicated health care professionals, a new study shows. ... need either hospitalization or a trip to the emergency room ... at the University of Texas in Houston versus usual care, ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Thousands of ... move forward in a number of multidistrict litigations currently ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... to convene a Joint Status Conference in all of ... Parties have been directed to submit a proposed agenda ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... , ... has established a strong link between elevated commitment among employees and positive business outcomes. ... Charlotte, NC ... host a webinar titled “Building Workforce Commitment.” The free hour-long webinar will be ...
... ... clients, connecting them with the best-in-class partners around the world, delivering the ultimate experience ... ... a different connotation today than the decades old call center depiction. Clients today ...
... Hospitals ... use” of certified Electronic Medical Record (EMR) systems under the American Recovery and Reinvestment ... ... (ARRA) hospitals and physicians can receive $19 billion in subsidies over five years for ...
... ... SEO firm in 2001 under the name of Anna Tulchinsky Web Consultancy, Joomla Bliss was ... quality or professionalism. The firm is offering several website design + SEO packages tailored specifically ... , ...
... , ... on Interferential mode, is reducing the severity, duration and frequency of pain for many patients ... weeks between treatments. , ... March 9, 2010 -- The Infrex Plus Unit from MedFaxx, when used on Interferential Mode, ...
... ... ... , ... ...
Cached Medicine News:Health News:Morehead Webinar to Discuss Building Workforce Commitment 2Health News:Announcing the Evolution of Provider Placement Methodology – EPIC Connections 2Health News:Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds 2Health News:Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds 3Health News:Recession Buster for Small Businesses: Website Design and Search Engine Optimization on a Shoestring 2Health News:Recession Buster for Small Businesses: Website Design and Search Engine Optimization on a Shoestring 3Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 2Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 3Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 4Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 2Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 3Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 4Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 5Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 6Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 7Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 8Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 9
... CRP-HS assay utilizes turbidimetric immunoassay methodology which ... the range of 0.2-28.0 mg/dL. This assay ... to most clinical chemistry analyzers. The Wako ... of precision, linearity, correlation, and sensitivity. Expected ...
... Piccolo is the first compact, broad ... patient testing in any treatment setting. Care ... electrolyte panels with less than one minute ... are comparable in quality to larger, expensive ...
... , The ADVIA 1200 system features a small footprint, ... laboratory. , , Standardization as Part of the ... the same reagents, calibrators and controls as the other ... on the same proven reliability. , , Meets ...
... Stryker BioZip Suture Anchor is a unique double ... BioZip is made from Poly-L Lactic Acid (PLLA) ... Needles are attached to the suture ends for ... arthroscopic repairs. The trocar tip inserter allows insertion ...
Medicine Products: